Menu

Speaking of Cancer Research

Notable quotes from this year’s annual meeting of the American Association for Cancer Research

Apr 5, 2017
Jef Akst

JEF AKST

“This is no time to undercut progress, for God’s sake. It’s no time to let up. It’s time to double down. It’s time we deliver on the promise of science and technology to extend and improve lives.”

—Former US Vice President Joe Biden

 

“Funding for cancer research isn’t something you can turn on and off like a faucet.”

Nancy Davidson, AACR President

 

“There has been a revolution in cancer research in the past decade. If I were to summarize that revolution in one sentence it would be: cancer results from the sequential accumulation of genomic alterations. . . . The challenge for all of us here to today is to achieve the next revolution, and that is to dramatically reduce deaths from cancer.”

Bert Vogelstein, Johns Hopkins Medicine

 

“At first blush, the problem of [cancer drug] resistance seems insurmountable. It’s multifactorial and heterogeneous. There can be multiple resistance mechanisms operating in a particular patient.”

Levi Garraway, Eli Lilly

 

“Early detection doesn’t have to be very early. . . . It takes years, perhaps decades, for a [malignancy] to evolve into a widely metastatic lesion, offering a huge window of opportunity to detect those cancers and intervene in the process.”

Vogelstein

 

“In our fight against cancer, we have to be unwilling to postpone for even a second. . . . Let’s keep it going, folks. This is no time to stop the momentum.”

Biden

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!